-
Something wrong with this record ?
Gene expression profile of intestinal organoids from people with cystic fibrosis upon exposure to elexacaftor/tezacaftor/ivacaftor
O. Cinek, E. Furstova, S. Novotna, K. Hubackova, T. Dousova, L. Borek-Dohalska, P. Drevinek
Language English Country Netherlands
Document type Journal Article
- MeSH
- Chloride Channel Agonists therapeutic use pharmacology MeSH
- Aminophenols * therapeutic use pharmacology MeSH
- Benzodioxoles * therapeutic use pharmacology MeSH
- Quinolones * pharmacology therapeutic use MeSH
- Cystic Fibrosis * genetics drug therapy MeSH
- Drug Combinations MeSH
- Indoles * pharmacology MeSH
- Humans MeSH
- Organoids * metabolism MeSH
- Cystic Fibrosis Transmembrane Conductance Regulator genetics MeSH
- Pyrazoles * pharmacology MeSH
- Pyridines pharmacology MeSH
- Pyrrolidines pharmacology MeSH
- Pyrroles pharmacology MeSH
- Gene Expression Profiling methods MeSH
- Intestines drug effects MeSH
- Transcriptome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
The forskolin-induced swelling assay (FIS) in patient-derived intestinal organoids (PDIOs), used to determine in vitro responsiveness to elexacaftor/tezacaftor/ivacaftor (ETI), showed variability in swelling among PDIOs obtained from people with CF (pwCF) carrying the same F508del/F508del CFTR genotype. We aimed to characterise the effect of ETI on the transcriptional activity of PDIOs-derived cells to understand the intracellular processes triggered by ETI and the differences in treatment response. Six high- and six low-responding PDIOs to ETI, derived from F508del/F508del pwCF, were incubated with or without ETI for 2 to 6 h. Gene expression was assessed using 3'-mRNA sequencing and modelled using negative binomial models. Incubation with ETI resulted in a significant upregulation of several biological processes: mostly related to chemokines and signalling, chemotaxis, and tissue development processes. No changes were observed in abundance of the CFTR transcripts or in CFTR-related gene sets and pathways. The genes and pathways associated with ETI did not overlap with those whose expression changed with time only. PDIOs with a high FIS response did not significantly differ in any interpretable gene from the FIS-low organoids. The changes in the PDIOs gene expression upon the exposure to ETI cannot explain differences in the magnitude of PDIOs FIS-measured response to ETI. In conclusion, on incubation with ETI, genes of the CFTR-related pathways do not change their transcriptional activity; instead, overexpression was observed in genes of inflammatory-like cytokine response and receptor activation pathways.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25010513
- 003
- CZ-PrNML
- 005
- 20250429134924.0
- 007
- ta
- 008
- 250415s2025 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jcf.2024.09.005 $2 doi
- 035 __
- $a (PubMed)39278758
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Cinek, Ondrej $u Department of Medical Microbiology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czechia; Department of Paediatrics, Second Faculty of Medicine Charles University and Motol University Hospital, Prague, Czechia. Electronic address: Ondrej.Cinek@Lfmotol.cuni.cz
- 245 10
- $a Gene expression profile of intestinal organoids from people with cystic fibrosis upon exposure to elexacaftor/tezacaftor/ivacaftor / $c O. Cinek, E. Furstova, S. Novotna, K. Hubackova, T. Dousova, L. Borek-Dohalska, P. Drevinek
- 520 9_
- $a The forskolin-induced swelling assay (FIS) in patient-derived intestinal organoids (PDIOs), used to determine in vitro responsiveness to elexacaftor/tezacaftor/ivacaftor (ETI), showed variability in swelling among PDIOs obtained from people with CF (pwCF) carrying the same F508del/F508del CFTR genotype. We aimed to characterise the effect of ETI on the transcriptional activity of PDIOs-derived cells to understand the intracellular processes triggered by ETI and the differences in treatment response. Six high- and six low-responding PDIOs to ETI, derived from F508del/F508del pwCF, were incubated with or without ETI for 2 to 6 h. Gene expression was assessed using 3'-mRNA sequencing and modelled using negative binomial models. Incubation with ETI resulted in a significant upregulation of several biological processes: mostly related to chemokines and signalling, chemotaxis, and tissue development processes. No changes were observed in abundance of the CFTR transcripts or in CFTR-related gene sets and pathways. The genes and pathways associated with ETI did not overlap with those whose expression changed with time only. PDIOs with a high FIS response did not significantly differ in any interpretable gene from the FIS-low organoids. The changes in the PDIOs gene expression upon the exposure to ETI cannot explain differences in the magnitude of PDIOs FIS-measured response to ETI. In conclusion, on incubation with ETI, genes of the CFTR-related pathways do not change their transcriptional activity; instead, overexpression was observed in genes of inflammatory-like cytokine response and receptor activation pathways.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a cystická fibróza $x genetika $x farmakoterapie $7 D003550
- 650 12
- $a organoidy $x metabolismus $7 D009940
- 650 12
- $a benzodioxoly $x terapeutické užití $x farmakologie $7 D052117
- 650 12
- $a aminofenoly $x terapeutické užití $x farmakologie $7 D000627
- 650 12
- $a chinolony $x farmakologie $x terapeutické užití $7 D015363
- 650 12
- $a indoly $x farmakologie $7 D007211
- 650 12
- $a pyrazoly $x farmakologie $7 D011720
- 650 _2
- $a fixní kombinace léků $7 D004338
- 650 _2
- $a protein CFTR $x genetika $7 D019005
- 650 _2
- $a pyrroly $x farmakologie $7 D011758
- 650 _2
- $a aktivátory chloridových kanálů $x terapeutické užití $x farmakologie $7 D065101
- 650 _2
- $a transkriptom $7 D059467
- 650 _2
- $a pyridiny $x farmakologie $7 D011725
- 650 _2
- $a střeva $x účinky léků $7 D007422
- 650 _2
- $a stanovení celkové genové exprese $x metody $7 D020869
- 650 _2
- $a pyrrolidiny $x farmakologie $7 D011759
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Furstova, Eva $u Department of Paediatrics, Second Faculty of Medicine Charles University and Motol University Hospital, Prague, Czechia
- 700 1_
- $a Novotna, Stepanka $u Department of Medical Microbiology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czechia
- 700 1_
- $a Hubackova, Klara $u Department of Medical Microbiology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czechia
- 700 1_
- $a Dousova, Tereza $u Department of Paediatrics, Second Faculty of Medicine Charles University and Motol University Hospital, Prague, Czechia
- 700 1_
- $a Borek-Dohalska, Lucie $u Department of Medical Microbiology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czechia
- 700 1_
- $a Drevinek, Pavel $u Department of Medical Microbiology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czechia
- 773 0_
- $w MED00006892 $t Journal of cystic fibrosis $x 1873-5010 $g Roč. 24, č. 1 (2025), s. 157-163
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39278758 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429134920 $b ABA008
- 999 __
- $a ok $b bmc $g 2311712 $s 1247594
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 24 $c 1 $d 157-163 $e 20240914 $i 1873-5010 $m Journal of cystic fibrosis $n J Cyst Fibros $x MED00006892
- LZP __
- $a Pubmed-20250415